FDA Grants Breakthrough Therapy Designation to bb2121 for Multiple Myeloma

Share this content:
Breakthrough Therapy Designation was granted for bb2121, a novel CAR T-cell therapy indicated for patients with multiple myeloma who have undergone previous treatments.
Breakthrough Therapy Designation was granted for bb2121, a novel CAR T-cell therapy indicated for patients with multiple myeloma who have undergone previous treatments.

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to bb2121 — a chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) — for patients with previously treated multiple myeloma (MM), according to a news release from Celgene Corporation.

The FDA based its approval on preliminary evidence from the ongoing CRB-401 phase 1 study. For this study, researchers infused 21 patients with MM who had received at least 3 previous lines of therapy with bb2121.

After a median follow-up of 15.4 weeks, the overall response rate was 89%, and increased to 100% for patients treated with 150×106 CAR+ T-cells or greater. Patients who were treated with 150×106 CAR+ T-cells or higher did not experience disease progression with time between 8 and 54 weeks since bb2121 exposure.

At the time of data cut-off, no grade 3 or higher treatment-emergent neurotoxicites were reported. Primarily grade 1 to 2 cytokine release syndrome (CRS) was observed in 71% of patients; 2 patients experienced grade 3 CRS that resolved in 24 hours; and 4 patients were treated with tocilizumab, and 1 with steroids, to manage their CRS symptoms.

Breakthrough Therapy Designation is granted by the FDA to agents that may significantly improve at least one clinical outcome for a serious or life-threatening disease in order to quicken the development, review, and potential approval of these medications.

Reference

1. Celgene Corporation and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted breakthrough therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma [news release]. Summit, NJ; Cambridge, MA: Celgene Corporation; bluebird bio; November 16, 2017. http://www.businesswire.com/news/home/20171116005818/en/Celgene-Corporation-bluebird-bio-Announce-bb2121-Anti-BCMA. Accessed November 27, 2017.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs